STK11
STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Overview
Tumour suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53.
CIViC holds 23 clinical evidence items and 0 assertions across 8 variants, naming Sirolimus, MEK Inhibitor CI-1040, Everolimus and Cisplatin/Pembrolizumab/Pemetrexed Regimen and others. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes genetic literature 0.75, affected pathway 0.96, literature 1.00, genetic association 0.72, somatic mutation 0.96, animal model 0.77). IntOGen calls it a driver in 14 cohorts (3 activating, 11 loss-of-function), covering Anal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Cancer and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 1 · What it is
STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
- 2 · What goes wrong in cancer
Tumour suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response.
- 3 · How drugs use it
No product in this corpus aims at STK11 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:11389 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q15831 (protein name, function text, keywords and locations (REST API)); CIViC gene STK11 (23 evidence items, 0 assertions, 8 variants; diseases: Lung Non-small Cell Carcinoma, Peutz-Jeghers Syndrome, Breast Cancer, Lung Adenocarcinoma, Prostate Cancer and 2 more (GraphQL API, CC0)); Open Targets ENSG00000118046 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.74, colorectal cancer 0.53, gastric cancer 0.53, ovarian cancer 0.64, cervical cancer 0.61, melanoma 0.63 (GraphQL API, CC0)); IntOGen STK11 (driver in 14 cohorts (Act 3, LoF 11); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Tumour suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA, PTEN and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2 and thereby regulates processes including: inhibition of signalling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, and B-cell differentiation in the germinal centre in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neuron polarisation by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Location: Nucleus; Cytoplasm; Membrane; Mitochondrion (UniProt). Locus 19p13.3 (HGNC).
- Lung cancer: Open Targets association 0.75 with lung cancer (MONDO_0008903)
- Ovarian cancer: Open Targets association 0.64 with ovarian cancer (MONDO_0008170)
- Cervical cancer: Open Targets association 0.61 with cervical cancer (MONDO_0002974); IntOGen driver in 3 cohorts (CEAD, CESC)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Prostate cancer: CIViC evidence names this disease
- Pancreatic ductal adenocarcinoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 17 therapies; IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 11 cohorts; CIViC holds 23 clinical evidence items on its variants; UniProt keyword "DNA damage". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Peutz-Jeghers Syndrome.
Latest papers
topQuery for this target: (TITLE:"STK11" OR ABSTRACT:"STK11" OR TITLE:"serine/threonine kinase 11" OR ABSTRACT:"serine/threonine kinase 11" OR TITLE:"Serine/threonine-protein kinase STK11" OR ABSTRACT:"Serine/threonine-protein kinase STK11" OR TITLE:"LKB1" OR ABSTRACT:"LKB1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STK11, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKEAP1
Shares A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1, A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS, KEAP1-NRF2 antioxidant pathway, Lung cancer (all types).
- TargetCHEK2
Shares Thyroid cancer, Lung cancer (all types), Breast cancer (all types), CIViC.
- TargetPALB2
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetSMAD3
Shares Thyroid cancer, Lung cancer (all types), Breast cancer (all types), CIViC.
- TargetETV1
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetBARD1
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetFAT1
Shares Lung cancer (all types), Cervical cancer, Breast cancer (all types), CIViC.
- TargetDROSHA
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.